- PLN124.77m
- PLN151.42m
- PLN15.76m
Brief: Mabion Q2 Net Loss At 15.4 Million Zlotys
Brief: Mabion Q2 Net Loss At 15.4 Million Zlotys
Brief: Mabion Receives Term Sheet From Twiti Investments
Brief: Mabion Appoints Gregor Kawaletz As CEO
Brief: Mabion Director For Business Development Adam Pietruszkiewicz Resigns From Management Board
Brief: Novalgen To Begin World’s First Clinical Trial For A Self-Regulating Immunotherapy
Brief: Mabion Says Krzysztof Kaczmarczyk Dismissed As CEO
Brief: Mabion Signs New Deal With Brazil's IBMP For Drug Manufacturing Technology Transfer
Brief: Mabion Says Conditions For Order From IBMP Get Fulfilled
Brief: Mabion Says Delivery Date Extended To Q4 Under Annex To Deal With Bonfiglioli Engineering
Brief: Mabion Q1 Net Loss 15.3 Mln Zlotys
Brief: Mabion Fulfills Condition For Deal With WPD Pharmaceuticals
Brief: Mabion FY Net Loss 6.3 Mln Zlotys
Brief: Mabion Adopts Strategy For 2025-2030
Brief: Mabion Signs About 2 Mln Zloty Deal With WPD Pharmaceuticals
Brief: Mabion Signs Strategic Cooperation Deal With Sartorius
Brief: Mabion Sigs Framework Deal With IBMP For Clinical Supply Services
Brief: Mabion Concludes Annex To Deal With Bonfiglioli Engineering
Brief: Mabion To Withdraw From Project And Funding Agreement